RPL17 and neoplasm: Novel CAR.αPD1-T cells were generated based on the anti-CD19 CAR, and constitutive anti-PD-1 secretion was more efficient in tumor eradication than parental anti-CD19 CAR T cells in human lung carcinoma xenograft tumors [97].